Fibroma, a Noval Side Effect of Chimeric Antigen Receptor (Car)T-Cell Immunotherapy in a Patient with Diffuse Large B-CellLymphoma: A Case Report

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. The U.S. FDA has approved the anti-CD19 CAR T-cell product tisagenlecleucel for multiply relapsed or refractory adult diffuse large B-cell lymphoma (DLBCL). There are many adverse effects after CAR T-cell therapy; primarily reported cytokine release syndrome (CRS) and neurologic toxicity, including fevers, hypotension, hypoxia, end organ dysfunction, cytopenias, coagulopathy, hemophagocytic lymphohistiocytosis, encephalopathy, cognitive defects, dysphasias, seizures and cerebral edema. Some adverse effects are rare, eg, fibroma. We report a new case of a 62-year-old female who experienced fibroma after CAR T-cell therapy.